Bonecure Platform
ASC pre-differentiated to osteoblasts in Histobone scaffold (engineered synthetic bone substitute) for the treatment of bone defects caused by pseudoarthrosis, infections, resections, trauma).
Clinical Phase II ongoing Q2 2018 with allogenic product.
Licensing & co-development agreement with Salvat.
2017: 6 patients treated with Bonecure autologous product and medical discharged as bone consolidation has been achieved.
Recruitment of phase II was completed in 2019.
2018-2020: evaluation of the clinical trial with 6 patients treated with allogeneic Bonecure.
Regenerative capabilities of cells.
Guided osseous re-modelling process due to scaffold properties.
Excellent integration of newly formed tissue with surrounding tissue.
Adequate revascularisation.